Table 2.
CYP2D6 inhibitors, substrates, and inducers used to adjust the association between breast cancer recurrence and ever/never use of citalopram or other SSRI.
| Drug action & ATC Name | ATC code | ERP+/TAM+ cases/controls | ERP−/TAM− cases/controls |
|---|---|---|---|
| Histamine blocker | |||
| Cimetidine | A02BA01 | 9/9 | 3/4 |
| Ranitidine | A02BA02 | 0/2 | 2/0 |
| Antiemetic | |||
| Metoclopramide | A03FA01 | 12/5 | 12/1 |
| Ondansetron | A04AA01 | 2/0 | 0/0 |
| Antifungal | |||
| Terbinafine | D01BA02 | 0/2 | 0/1 |
| Antiarrythmia | |||
| Flecainid | C01BC04 | 1/0 | 0/0 |
| Amiodarone | C01BD01 | 0/0 | 0/1 |
| Beta blocker | |||
| Propranolol | C07AA05 | 5/0 | 2/1 |
| Metoprolol | C07AB02 | 10/0 | 3/4 |
| Timolol | S01ED01 | 3/0 | 0/0 |
| Antihypertensive | |||
| Carvedilol | C07AG02 | 1/0 | 1/0 |
| Non-steroidal antiinflammatory | |||
| Celecoxib | M01AH01 | 12/7 | 4/1 |
| Analgesic | |||
| Tramadola | N02AX02 | 45/18 | 0/0 |
| Codeinea | R05DA04 | 12/9 | 0/0 |
| Oxycodonea | N02AA05 | 12/0 | 0/0 |
| Antipsychotic | |||
| Chlorpromazin | N05AA01 | 0/0 | 0/2 |
| Levomepromazin | N05AA02 | 1/1 | 3/1 |
| Haloperidol | N05AD01 | 1/0 | 1/0 |
| Zuclopenthixol | N05AF05 | 1/1 | 2/2 |
| Perphenazine | N05AB03 | 0/1 | 2/0 |
| Risperidone | N05AX08 | 0/1 | 0/0 |
| TCA Antidepressants | |||
| Clomipramine | N06AA04 | 0/0 | 0/1 |
| Amitriptyline | N06AA09 | 3/7 | 5/3 |
| Nortriptyline | N06AA10 | 0/2 | 4/1 |
| Other Antidepressants | |||
| Moclobemid | N06AG02 | 1/0 | 0/0 |
| Mirtazapin | N06AX11 | 9/10 | 4/2 |
| Venlafaxin | N06AX16 | 6/2 | 0/1 |
| Opioids | |||
| Methadonea | N07BC02 | 0/1 | 0/0 |
| Cough Suppressants | |||
| Dexthromethorphan | R05DA09 | 0/1 | 0/0 |
| Steroid Hormone | |||
| Dexamethasonea | S01BA01 | 2/1 | 0/0 |
a
Not included in the adjustment for ever/never use of a CPY2D6 inhibitor or substrate because the drug may be used to treat breast cancer recurrence or its symptoms.